
JAKi and IL-4/-13i Show Similar Safety Profiles in AD
Janus kinase inhibitors (JAKi) have emerged as an effective systemic therapy for moderate to severe atopic dermatitis (AD), offering rapid and substantial symptom relief for many patients. However, long-standing safety concerns—particularly regarding …